This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Querfeld, U. Articles by Zeisel, H.-J. Search for Related Content PubMed PubMed Citation Articles by Querfeld, U. Articles by Zeisel, H.-J.

Long-Term Treatment with Growth Hormone Has No Persisting Effect on Lipoprotein(a) in Patients with Turner’s Syndrome

Departments of Pediatrics and Medical Statistics (P.K.), University of Cologne, 50924 Cologne, Germany; and Clinical Research Institute (H.-J.Z.), 79232 March, Germany

Address all correspondence and requests for reprints to: Uwe Querfeld, M.D., University Children’s Hospital, Joseph-Stelzmann-Strasse 9, 50924 Cologne, Germany. E-mail: uwe.querfeld{at}uni-koeln.de

Treatment with recombinant human GH (rhGH), alone or in combination with the anabolic steroid oxandrolone (OX), has been recommended for girls with Turner’s syndrome to improve final height. Several cardiovascular risk factors have been described in patients with Turner’s syndrome, but the effect of therapy with rhGH and OX on lipoprotein(a) [Lp(a)] has not been investigated. Lp(a) serum levels and apolipoprotein(a) phenotypes were determined in 46 girls with Turner’s syndrome (aged 6–15 yr) during treatment with different combinations of rhGH and OX for 24–36 months (median, 27 months). Lp(a) serum levels showed little variation during 30 months of treatment in all treatment groups. Lp(a) levels showed no significant change in 25 patients receiving only rhGH and in 21 patients receiving rhGH and OX in combination. Treatment effects were independent of apolipoprotein(a) phenotypes and were not influenced by pubertal status. These data indicate that long term administration of rhGH has no significant impact on serum Lp(a) levels in girls with Turner’s syndrome.

This article has been cited by other articles:

				K. Landin-Wilhelmsen, I. Bryman, and L. Wilhelmsen Cardiac Malformations and Hypertension, But Not Metabolic Risk Factors, Are Common in Turner Syndrome J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4166 - 4170. [Abstract] [Full Text] [PDF]